CN Patent

CN109563036A — 匹莫范色林酒石酸盐的新晶型及其制备方法和用途

Assigned to Shanghai Begreat Pharmatech · Expires 2019-04-02 · 7y expired

What this patent protects

N‑(4‑氟苄基)‑N‑(1‑甲基哌啶‑4‑基)‑N’‑[4‑(2‑甲基丙氧基)苯基甲基]脲酒石酸盐的新多晶型III及其制备方法和药用用途。与现有晶型相比，新晶型在溶解度、稳定性和制备工艺方面具有明显优势。

USPTO Abstract

N‑(4‑氟苄基)‑N‑(1‑甲基哌啶‑4‑基)‑N’‑[4‑(2‑甲基丙氧基)苯基甲基]脲酒石酸盐的新多晶型III及其制备方法和药用用途。与现有晶型相比，新晶型在溶解度、稳定性和制备工艺方面具有明显优势。

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: CN109563036A
Jurisdiction: CN
Classification: —
Expires: 2019-04-02
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Begreat Pharmatech
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.